Patents by Inventor Thomas Ichim

Thomas Ichim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250041351
    Abstract: Disclosed are compositions and methods of treating muscular dystrophies, including Duchenne Muscular Dystrophy (DMD) through administration of fibroblasts and modified fibroblasts systemically and locally. In certain embodiments, fibroblast cells are utilized for replacement of dystrophin through fusion and/or other means of horizontal gene transfer. In other embodiments, the disclosure teaches the use of fibroblasts for reduction of inflammatory reactions and/or immunological reactions which propagate and enhance myodestructive aspects of Duchenne Muscular Dystrophy. In other embodiments, fibroblasts are utilized as vectors for gene therapy and/or gene modifications approaches.
    Type: Application
    Filed: August 13, 2024
    Publication date: February 6, 2025
    Applicant: SPINALCYTE, LLC
    Inventors: Pete O'HEERON, Thomas ICHIM
  • Publication number: 20250041352
    Abstract: Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.
    Type: Application
    Filed: October 3, 2024
    Publication date: February 6, 2025
    Applicant: SPINALCYTE LLC
    Inventors: Pete O'HEERON, Thomas ICHIM
  • Publication number: 20250027044
    Abstract: Compositions of matter and means useful for treatment of autoimmunity and/or transplant rejection through generation of T regulatory cells in a manner that recapitulates thymic development. Methods of seeding thymic medullary epithelial cells with pluripotent stem cells such as inducible pluripotent stem cells, followed by exposure to conditions allowing for selective growth and expansion of T regulatory cells. T regulatory cells can be scaled for clinical utilization through the use of three-dimensional adhesive growth matrices as well as addition of FoxP3 inducing cytokines such as interleukin-2.
    Type: Application
    Filed: July 17, 2024
    Publication date: January 23, 2025
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Courtney Bartlett, Timothy Warbington, Amit Patel
  • Publication number: 20250002853
    Abstract: Cellular modifications useful for enhancing migratory potential of T regulatory cells that have been derived from inducible pluripotent stem cells. In one embodiment said inducible pluripotent stem cells are gene edited for insertion or deletion of cytoskeletal and motility associated genes in order to increase migration ability as well as deformability of cells in a manner allowing for increased extravasation and mobility. In other embodiments inducible pluripotent stem cell derived T regulatory cells are gene edited at the level of T Regulatory cell progenitor stage.
    Type: Application
    Filed: June 27, 2024
    Publication date: January 2, 2025
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Courney Bartlett, Timothy Warbington, Amit Patel
  • Publication number: 20240374723
    Abstract: The invention provides methods of inducing immunological tolerance to a transplanted cellular population or organ by creating and administering a “veto-like” cell originating from the identical genetic background of the organ donor. In one embodiment said artificially generated veto cell is a dendritic cell population possessing molecules associated with tolerance induced in natural anatomical locations such as the placenta, the testis, or the eye. In one embodiment dendritic cells resistant to maturation are generated from pluripotent stem cells that have been gene edited to lack genes needed for acquisition of antigen presenting properties such as relB, NF-kappa B and transporter associated protein. In another embodiment immature dendritic cells are gene edited/transfected to express tolerance associated molecules such as interleukin-10, interleukin-35, Fas ligand, TRAIL, TGF-beta, HLA-G and arginase.
    Type: Application
    Filed: April 25, 2024
    Publication date: November 14, 2024
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Amit Patel, Courtney Bartlett, Timothy Warbington
  • Publication number: 20240366677
    Abstract: The present disclosure provides means of inhibition and/or treating aneurysms and other degenerated blood vessels through administration of regenerative cell derived exosomes, and/or regenerative cell derived apoptotic bodies. In one particular embodiment vessel regeneration is increased through administration of stem cell exosomes/or stem cell apoptotic bodies. Other embodiments include regeneration of vessels prone to aneurysms, repairing aneurysms of vessels, or acceleration of endothelialization after stent placement. Provided within the invention are methods of rejuvenating properties of said vessels associated with physiological health, examples of which include appropriate production of anti-coagulating/clotting factors, control of angiogenesis, and appropriate revascularization of injured tissue.
    Type: Application
    Filed: May 1, 2024
    Publication date: November 7, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas Ichim, Timothy G. Dixon, James Veltmeyer
  • Publication number: 20240369541
    Abstract: Disclosed are methods and means of optimizing health of a subject during space travel comprising real time monitoring and intervention guided by automated and/or semiautomated means driven by a machine learning artificial intelligence-based system. In one embodiment the invention discloses the integration of genetic factors, biological properties, microbiome diversity, regenerative activity, and real time physiological changes in order to provide optimum interventions which result in increased health upon return from the space mission, as well as provide ability for said astronaut to endure space travel of increased durations.
    Type: Application
    Filed: April 26, 2024
    Publication date: November 7, 2024
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Courtney Bartlett, Timothy Warbington, Amit Patel
  • Publication number: 20240366760
    Abstract: Disclosed are means, methods and compositions of matter useful for stimulation of immunity to tumor antigens through isolation of dendritic cell exosomes from dendritic cells that have been pulsed with said tumor antigens and/or pulsed dendritic cells that have been gene silenced/gene edited for immune suppressive genes. In one embodiment said tumor antigen is survivin and said immune suppressive genes include interleukin-10, interleukin-35, TGF-beta and interleukin-13. In some embodiments dendritic cells are further transfected with immune stimulatory genes including interleukin-2, interleukin?12, interleukin-15 and interleukin-18.
    Type: Application
    Filed: January 17, 2024
    Publication date: November 7, 2024
    Applicant: Regen Biopharma, Inc.
    Inventors: Thomas ICHIM, David KOOS
  • Patent number: 12133870
    Abstract: Disclosed are methods and compositions comprising fibroblasts and/or products derived thereof for the inhibition and/or treatment of addiction of any kind, such as opioid addiction. In some embodiments, methods comprise treating a patient addicted to opioids by administering a fibroblast population at a concentration sufficient for suppression of addiction-associated brain damage. In some embodiments, the fibroblasts express CD31 and/or CD73 markers. In some embodiments, fibroblasts are used to endow neuronal regeneration in order to overcome changes in the brain associated with addiction. Some embodiments relate to the stimulation of hippocampal regeneration subsequent to addiction induced damage.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 5, 2024
    Assignee: SPINALCYTE LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Publication number: 20240352395
    Abstract: Disclosed are means of generating organs or organoids utilizing three-dimensional bio-printing processes. In one embodiment said organ is a pancreas or pancreas-like organ useful for the treatment of diabetes, wherein said bioprinted pancreas possesses enhanced regenerative activity, in some embodiments comparable to the liver due to seeding with enhanced numbers of regenerative cells. In another embodiment pancreatic islets are created capable of being utilized as a substitute for naturally occurring islets. In other embodiments immune-evasive organs are created utilizing combination of cells which possess ability to evade immunity, thus allowing for tolerance induction without need for immune suppressive activity.
    Type: Application
    Filed: April 15, 2024
    Publication date: October 24, 2024
    Applicant: Creative Medical Technologies, Inc.
    Inventors: Thomas Ichim, Timothy Warbington, Amit Patel, Courtney Bartlett
  • Publication number: 20240339176
    Abstract: Disclosed are systems, means and compositions of matter utilizing artificial intelligence to create unique cells and/or organs from pluripotent stem cells. In one embodiment an artificial intelligence/machine learning approach is utilized to overview and categorize molecular and cellular data regarding normal embryonic development and associated pathways. Through acquiring this information, said artificial intelligence/machine learning system develops a graded list of morphogens/differentiating agents and/or conditions that are utilized to replicate the process of cell/tissue/organ formation artificially. In one embodiment the invention teaches generation of artificial pancreatic organoids through growth factors predicted by said artificial intelligence/machine learning systems. In other embodiments embryogenesis is recapitulated in adult tissue using predicted morphogens and/or extracellular matrix treatments.
    Type: Application
    Filed: April 9, 2024
    Publication date: October 10, 2024
    Applicant: Creative Medical Technologies, Inc.
    Inventors: Thomas Ichim, Timothy Warbington, Amit Patel, Courtney Bartlett
  • Publication number: 20240331809
    Abstract: Disclosed are methods, means and systems of identifying compounds and augment T regulatory cell activity and/or number in vitro and/or in vivo utilizing deep learning approaches. Systems for screening compound libraries in silico are provided as well as laboratory methods of testing modulation of T regulatory cell activity and/or numbers. Results provided by the disclosure will serve as the basis for increasing T regulatory cells, which is desirable in situations of autoimmunity or organ transplantation. In situations of oncology or infectious disease reduction of T regulatory cell number and/or activity is desired.
    Type: Application
    Filed: April 1, 2024
    Publication date: October 3, 2024
    Applicant: CREATIVE MEDICAL TECHNOLOGIES, INC.
    Inventors: Thomas Ichim, Amit Patel, Timothy Warbington, Courtney Bartlett
  • Publication number: 20240307341
    Abstract: Unique compositions of matter and formulations useful for treatment of COVID-19. Said formulation function by induction of immune modulation, cellular protection, suppression of inflammation and suppression of viral infection. In one embodiment a formulation consists of therapeutic doses of various nutraceuticals include epigallocatechin gallate (EGCG), sulforaphane, and curcumin. In some embodiments, the preparation are utilized as a adjuvant therapeutic, while in other embodiments said formulation is utilized as a monotherapy. Various delivery mechanisms can be used, including oral, transdermal, sublingual, intrarectal and intravenous administration.
    Type: Application
    Filed: March 13, 2024
    Publication date: September 19, 2024
    Applicant: Chongcha (Fujian) Culture & Technology Co. Ltd.
    Inventors: Feng Lin, Thomas Ichim, Jingyun Wu, Ju Zhang
  • Patent number: 12090174
    Abstract: Disclosed are compositions and methods of treating muscular dystrophies, including Duchenne Muscular Dystrophy (DMD) through administration of fibroblasts and modified fibroblasts systemically and locally. In certain embodiments, fibroblast cells are utilized for replacement of dystrophin through fusion and/or other means of horizontal gene transfer. In other embodiments, the disclosure teaches the use of fibroblasts for reduction of inflammatory reactions and/or immunological reactions which propagate and enhance myodestructive aspects of Duchenne Muscular Dystrophy. In other embodiments, fibroblasts are utilized as vectors for gene therapy and/or gene modifications approaches.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: September 17, 2024
    Assignee: SPINALCYTE, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Publication number: 20240293468
    Abstract: Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.
    Type: Application
    Filed: May 9, 2024
    Publication date: September 5, 2024
    Applicant: Figene, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Publication number: 20240293469
    Abstract: Embodiments of the disclosure encompass methods and compositions for treatment of cancer utilizing fibroblasts that have been modified to enhance their ability to deliver one or more anti-cancer agents to an individual in need thereof. In particular embodiments, the fibroblasts have been modified to express one or more chemokine receptors and/or have been exposed to hypoxia to enhance their ability to home to cancer cells. In specific cases the modified fibroblasts are engineered to encompass an oncolytic virus as a tumor inhibitory agent.
    Type: Application
    Filed: May 9, 2024
    Publication date: September 5, 2024
    Applicant: Figene, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Publication number: 20240287459
    Abstract: The present disclosure provides means of regenerating/restoring aged and/or damaged tissue or treating a medical condition by providing an extracorporeal circuit containing cells, including fibroblasts or dedifferentiated fibroblasts. that are in contact with plasma but not blood cells extracorporeally in a manner allowing for exchange of factors between a subject and an extracorporeally residing mass of cells. The disclosure provides means of titrating factors produced by the extracorporeal regenerative cell mass, thus allowing for a regenerative effect.
    Type: Application
    Filed: May 9, 2024
    Publication date: August 29, 2024
    Applicant: Figene, LLC
    Inventors: Pete O'Heeron, Thomas Ichim
  • Publication number: 20240269192
    Abstract: The present disclosure concerns methods and compositions for treating or preventing or reducing the risk of having Amyotrophic Lateral Sclerosis (ALS) in an individual. In particular embodiments, there are methods and compositions related to administering to the individual a therapeutically effective amount of a population of fibroblasts, fibroblast exosomes, IL-2, or a combination thereof.
    Type: Application
    Filed: June 17, 2022
    Publication date: August 15, 2024
    Applicant: SPINALCYTE LLC
    Inventors: Thomas ICHIM, Pete O'HEERON
  • Publication number: 20240269193
    Abstract: Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and/or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.
    Type: Application
    Filed: March 25, 2024
    Publication date: August 15, 2024
    Applicant: FIGENE, LLC
    Inventors: Pete O'HEERON, Thomas ICHIM, Kristin COMELLA
  • Publication number: 20240263140
    Abstract: Embodiments of the disclosure include methods and compositions for use of prepared fibroblasts and/or conditioned media therefrom. In particular embodiments, the prepared fibroblasts have enhanced regenerative and may have an increase in secretion of one or more cytokines and/or growth factors; may have an increase in anti-apoptotic activity; and/or may have a modulated immunogenicity. In specific embodiments, the fibroblasts are prepared by exposure to hypoxia and/or carbon monoxide.
    Type: Application
    Filed: March 13, 2024
    Publication date: August 8, 2024
    Applicant: FIGENE, LLC
    Inventors: Pete O'Heeron, Thomas Ichim